![]() |
市場調査レポート
商品コード
1593462
核医学イメージング装置市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測、2024年~2031年Nuclear Imaging Equipment Market Size, Share, Growth Analysis, By Product (Single-Photon Emission Computed Tomography Imaging Systems, Hybrid PET Imaging Systems), By Application, By End User, By Region - Industry Forecast 2024-2031 |
||||||
|
核医学イメージング装置市場規模、シェア、成長分析、製品別、用途別、エンドユーザー別、地域別 - 産業予測、2024年~2031年 |
出版日: 2024年11月10日
発行: SkyQuest
ページ情報: 英文 189 Pages
納期: 3~5営業日
|
核医学イメージング装置の世界市場規模は、2022年に30億2,000万米ドルと評価され、2023年の32億5,000万米ドルから2031年には57億5,000万米ドルに成長し、予測期間(2024-2031年)のCAGRは7.41%で成長する見通しです。
核医学イメージング装置市場は、技術の進歩と診断精度の向上への注力の高まりにより、大きく成長する見通しです。PET/MRIやPET/CTを含むハイブリッド画像システムなどのイノベーションにより機能が強化され、放射性物質を用いたさまざまな病態のより正確な可視化と診断が可能になっています。慢性疾患の蔓延とヘルスケア支出の増加に伴い、こうした高度な画像診断ツールの需要は増加傾向にあります。しかし、市場は規制上のハードルや放射性物質の使用に伴う高コストなどの課題に直面しています。こうした障害にもかかわらず、特に規制当局が新技術の承認プロセスを簡素化し、ヘルスケア部門が患者体験の向上に重点を置くようになるにつれ、有望な成長機会が生まれています。放射性医薬品の開発が進み、タイムリーで正確な診断の重要性が認識されつつあることから、核医学イメージング装置市場は今後数年で大きく発展するものと思われます。全体として、革新的な画像ソリューションの統合と患者中心のアプローチの改善が、ヘルスケアにおけるこの重要なセクターの将来を形作ることが期待されています。
Global Nuclear Imaging Equipment Market size was valued at USD 3.02 billion in 2022 and is poised to grow from USD 3.25 billion in 2023 to USD 5.75 billion by 2031, growing at a CAGR of 7.41% during the forecast period (2024-2031).
The nuclear imaging equipment market is poised for significant growth, driven by advancements in technology and an increased focus on improving diagnostic accuracy. Innovations such as hybrid imaging systems, including PET/MRI and PET/CT, are enhancing functionality, allowing for more precise visualization and diagnosis of various medical conditions using radioactive materials. As chronic diseases become more prevalent and healthcare expenditures rise, the demand for these sophisticated imaging tools is on the rise. However, the market faces challenges, including regulatory hurdles and the high costs associated with the use of radioactive substances. Despite these obstacles, there are promising opportunities for growth, particularly as regulatory bodies simplify the approval process for new technologies and as the healthcare sector places greater emphasis on enhancing patient experience. With ongoing developments in radiopharmaceuticals and an increasing recognition of the importance of timely and accurate diagnostics, the nuclear imaging equipment market is set to experience substantial advancements in the coming years. Overall, the integration of innovative imaging solutions and improved patient-centric approaches is expected to shape the future of this vital sector in healthcare.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nuclear Imaging Equipment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Nuclear Imaging Equipment Market Segmental Analysis
Global Nuclear Imaging Equipment Market is segmented by Product, Application, End User, and Region. Based on Product, the market is segmented into Single-Photon Emission Computed Tomography (SPECT) Imaging Systems (Hybrid SPECT Imaging Systems, Standalone SPECT Imaging Systems), Hybrid PET Imaging Systems, Planar Scintigraphy Imaging Systems. Based on Application, the market is segmented into Oncology, Cardiology, Neurology, Other Applications. Based on End User, the market is segmented into Hospitals, Imaging Centers, Academic & Research Centers, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Nuclear Imaging Equipment Market
The Global Nuclear Imaging Equipment market is significantly driven by the emergence of hybrid systems like PET/MRI and PET/CT, which seamlessly integrate various imaging modalities to deliver unparalleled precision and comprehensive diagnostic information. This convergence of technologies not only improves imaging accuracy but also broadens the scope of conditions that can be diagnosed through nuclear imaging, thereby elevating awareness and clinical significance among healthcare providers and patients alike. Furthermore, advancements in radiopharmaceuticals have refined the imaging process, enhancing the efficacy and reliability of diagnoses, thus contributing robustly to the growth trajectory of the nuclear imaging market.
Restraints in the Global Nuclear Imaging Equipment Market
The Global Nuclear Imaging Equipment market faces significant restraints primarily due to the intricate and constrained development of radiopharmaceuticals essential for imaging procedures. Challenges related to production capacity and supply chain logistics can lead to critical shortages of these vital substances, hindering their availability in the market. Additionally, the inherent short half-lives of most radiopharmaceuticals necessitate rapid manufacturing and distribution, compounding the difficulty in meeting demand. Such complexities in production and quality control processes not only limit the supply of nuclear imaging agents but also pose substantial delays, ultimately restricting the overall growth potential of the nuclear imaging equipment sector.
Market Trends of the Global Nuclear Imaging Equipment Market
The Global Nuclear Imaging Equipment market is witnessing a notable trend driven by advancements in radiopharmaceuticals that enhance diagnostic capabilities across various diseases. Innovations in novel tracers are facilitating the detection of complex conditions such as cancer, cardiovascular diseases, and neurological disorders. Moreover, the rise of theragnostic approaches-integrating targeted therapy with diagnostic imaging-is gaining traction, particularly in oncology, allowing for personalized treatment plans. This convergence of diagnostics and therapeutics is expected to augment market growth, as healthcare providers increasingly adopt these advanced technologies to improve patient outcomes and streamline treatment processes, ultimately reshaping the landscape of medical imaging.